Literature DB >> 15843207

Hematopoietic cytokines in the sera of patients with pancreatic cancer.

Barbara Mroczko1, Maciej Szmitkowski, Urszula Wereszczyńska-Siemiatkowska, Grazyna Jurkowska.   

Abstract

Hematopoietic cytokines (HCs) can affect the growth and spread of cancer. Therefore, in the present study, we investigated in pancreatic cancer patients the serum levels of selected HCs, such as stem cell factor (SCF), interleukin 3 (IL-3), granulocyte-macrophage-colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF) and macrophage-colony stimulating factor (M-CSF) in relation to a control group and to a group of patients with chronic pancreatitis. Classical tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) were also tested. We compared the serum level of cytokines with the tumor stage. The diagnostic sensitivity, specificity, positive and negative predictive values and receiver-operating characteristics (ROC) curve for cytokines and classical tumor markers were defined. The cytokines were measured in 48 patients with pancreatic cancer, in 23 patients with chronic pancreatitis and in 40 healthy subjects. HCs were determined using ELISA. CEA and CA 19-9 were measured by microparticle enzyme immunoassay. There were significant differences in the levels of circulating SCF, IL-3, GM-CSF, M-CSF, CEA and CA 19-9 in the pancreatic cancer patients compared to the control group. The serum levels of M-CSF and tumor markers were significantly higher in pancreatic cancer patients compared to the pancreatitis group. The levels of SCF, M-CSF and tumor markers were higher in patients with a more advanced tumor stage. The M-CSF serum levels in the pancreatitis group correlated positively with the tumor markers tested--CEA and CA 19-9. The diagnostic sensitivity of SCF and specificity of M-CSF and tumor markers were the highest. The SCF and M-CSF areas under the ROC curve were greater than the areas for other cytokines. These results suggest the potential usefulness of HCs in pancreatic cancer detection; however, further investigations of early-stage pancreatic cancer patients and confirmation by a prospective study are necessary.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843207     DOI: 10.1515/CCLM.2005.024

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.

Authors:  Yuliya Pylayeva-Gupta; Kyoung Eun Lee; Cristina H Hajdu; George Miller; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

2.  MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition.

Authors:  L D Roy; M Sahraei; D B Subramani; D Besmer; S Nath; T L Tinder; E Bajaj; K Shanmugam; Y Y Lee; S I L Hwang; S J Gendler; P Mukherjee
Journal:  Oncogene       Date:  2010-11-22       Impact factor: 9.867

3.  Selected cytokines in patients with pancreatic cancer: a preliminary report.

Authors:  Wojciech Błogowski; Anna Deskur; Marta Budkowska; Daria Sałata; Anna Madej-Michniewicz; Krzysztof Dąbkowski; Barbara Dołęgowska; Teresa Starzyńska
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

Review 4.  Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.

Authors:  Yandiswa Yolanda Yako; Deirdré Kruger; Martin Smith; Martin Brand
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

5.  Stem cell factor in the serum of patients with esophageal cancer in relation to its histological types.

Authors:  Marta Łukaszewicz-Zając; Barbara Mroczko; Mirosław Kozłowski; Maciej Szmitkowski
Journal:  Arch Med Sci       Date:  2016-08-09       Impact factor: 3.318

Review 6.  Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?

Authors:  Robert S O'Neill; Alina Stoita
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.